Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report

Minoru Ito\textsuperscript{a}  Takumi Kawaguchi\textsuperscript{a, b}  Eitaro Taniguchi\textsuperscript{a}  Tetsuharu Oriishi\textsuperscript{a}  Michio Sata\textsuperscript{a, b}

\textsuperscript{a}Division of Gastroenterology, Department of Medicine, and \textsuperscript{b}Department of Digestive Disease Information and Research, Kurume University School of Medicine, Kurume, Japan

Key Words
Dipeptidyl peptidase IV · Incretin · Nonalcoholic fatty liver disease · Nonalcoholic steatohepatitis · Glucose intolerance · Diabetes

Abstract
A 67-year-old Asian woman was referred to Kurume University Hospital due to abnormal liver function tests. She was diagnosed with nonalcoholic fatty liver disease (NAFLD). NAFLD was treated by diet therapy with medication of metformin and pioglitazone; however, NAFLD did not improve. Subsequently, the patient was administered sitagliptin. Although her energy intake and physical activity did not change, her hemoglobin A1c level was decreased from 7.8 to 6.4\% 3 months after treatment. Moreover, her serum insulin level and homeostasis model assessment-insulin resistance value were also improved, as was the severity of hepatic steatosis. These findings indicate that sitagliptin may improve insulin resistance and steatosis in patients with refractory NAFLD.

Introduction
The prevalence of nonalcoholic fatty liver disease (NAFLD) is rapidly increasing worldwide [1]. Over 5\% of NAFLD patients develop advanced liver cirrhosis [2]. NAFLD patients also present with complicating hepatocellular carcinoma [3, 4] and
extrahepatic malignancies [5] and show a poor prognosis compared to the general population [6]. Therefore, NAFLD is recognized as an important therapeutic target [4, 7].

NAFLD is frequently accompanied by insulin resistance/type 2 diabetes mellitus. Insulin-sensitizing agents have recently been reported to have a beneficial effect on NAFLD. Metformin, an insulin sensitizer, increases hepatic lipid and glucose catabolism, resulting in improved insulin resistance and hepatic steatosis in patients with NAFLD [8–10]. Pioglitazone, another insulin-sensitizing agent that modulates peroxisome proliferator-activated receptor-γ (PPARγ), reduces hepatic steatosis by enhancing fatty acid oxidation and by inhibiting hepatic fatty acid synthesis in patients with NAFLD [11, 12]. However, use of these agents alone is not always sufficient in the treatment of NAFLD [13, 14]; as such, use of additional agents is required for patients with refractory NAFLD.

Sitagliptin is an inhibitor of dipeptidyl peptidase IV (DPP-4) and enhances the effect of glucagon-like peptide-1 (GLP-1) [15, 16]. GLP-1, a gut hormone, is known to regulate glucose metabolism by activating the GLP-1 receptor expressed in various tissues including the brain, pancreas and muscles [17–22]. Recently, Gupta et al. [23] demonstrated that the GLP-1 receptor exists in hepatocytes. In fact, GLP-1 reduced hepatic steatosis in ob/ob mice by improving insulin sensitivity [24]. Since sitagliptin up-regulates GLP-1 activity, the agent may be a potential therapeutic option for patients with NAFLD. Here we report a case of refractory NAFLD who was improved by sitagliptin treatment.

Case Report

A 67-year-old Asian woman was referred to the Digestive Disease Center, Kurume University Hospital due to abnormal liver function tests. The patient had been diagnosed with type 2 diabetes mellitus at 57 years of age. Biochemical tests showed elevated serum levels of aspartate aminotransferase, alanine aminotransferase and γ-glutamyl transpeptidase (table 1). Hepatitis viral makers including hepatitis B surface antigen, hepatitis B core antibody and antibody to hepatitis C virus were negative. Biochemical tests also showed no evidence of autoimmune chronic liver disease or genetic liver diseases such as Wilson disease or hemochromatosis (table 1).

Ultrasonography revealed a bright liver with deep attenuation and liver–kidney contrast, suggestive of sever fatty liver. The patient had no history of alcohol intake. Her average energy intake was 35 kcal/day/kg ideal body weight and fat intake was 25%. Her body mass index was 37.5 and her lifestyle was hypokinetic. In addition, she had an increased serum ferritin level and an increased hepatic steatosis in ob/ob mice by improving insulin sensitivity [24]. Since sitagliptin up-regulates GLP-1 activity, the agent may be a potential therapeutic option for patients with NAFLD. Here we report a case of refractory NAFLD who was improved by sitagliptin treatment.

Since the patient suffered from lumbago and leg pain, she could not perform exercise therapy. Thus, the NAFLD was managed by diet education. She understood the importance of diet therapy and reduced her energy and fat intake, however, her HOMA-IR score and hepatic steatosis severity did not improve (fig. 1). To improve her insulin resistance, she was prescribed metformin 750 mg/day. Despite the use of this anti-diabetic agent, HOMA-IR score and hepatic steatosis severity did not improve (fig. 1, fig. 2). Consequently, pioglitazone 15 mg/day was administered. Although her HOMA-IR score finally decreased, she experienced leg edema and a pericardial effusion (fig. 1, fig. 2). Pioglitazone was then withdrawn and her HOMA-IR score subsequently increased (fig. 1).

The patient was then administered sitagliptin 50 mg/day. Despite no change in her energy intake or physical activity, her hemoglobin A1c level decreased from 7.8 to 6.6% 4 months after treatment. Moreover, serum insulin level and HOMA-IR score also improved (fig. 1). In addition, the severity of
fatty accumulation in the liver decreased (fig. 2) and serum alanine aminotransferase level decreased to 35 IU/dl. These findings indicated that sitagliptin improved insulin resistance and steatosis in a patient with refractory NAFLD.

Discussion

Here we presented a case of refractory NAFLD treated by sitagliptin, a DPP-4 inhibitor. Although the patient had been treated with other anti-diabetic agents, both insulin resistance and steatosis severity were improved after sitagliptin treatment, suggesting efficacy of the DPP-4 inhibitor for patients with refractory NAFLD.

Chronic caloric overconsumption is a major causative factor of NAFLD [25]. In fact, the patient’s energy intake was high and, therefore, diet therapy was implemented. She understood the importance of diet therapy and reduced her energy intake; however, HOMA-IR value and steatosis severity did not improve. One possible reason is that exercise therapy, a first-line therapy for NAFLD [26, 27], was difficult to perform for this patient because of lumbago and leg pain. In addition to hypoactivity, an unknown metabolic abnormality may exist in this case, because the patient’s HOMA-IR value and serum free fatty acid level were extremely high compared to the reference values.

Since previous studies have shown that metformin is effective in patients with NAFLD, we administered that medication first. However, in this case the severity of insulin resistance and hepatic steatosis did not decrease with metformin treatment. Lavine et al. [13] reported similar results, namely that metformin treatment did not improve hepatic steatosis in patients with NAFLD. Thus the effectiveness of metformin on NAFLD remains controversial, possibly because NAFLD has various etiologies, including overnutrition, drugs and genetic diseases.

We added pioglitazone to the patient’s medication regimen. Addition of this drug decreased the patient’s HOMA-IR value from 7.5 to 7.0%, however it was discontinued due to the development of leg edema and pericardial effusion. Plasma volume expansion is a major adverse effect of PPARγ agonists such as pioglitazone [28], which stimulate epithelial sodium channel (ENaC)-mediated renal salt absorption in the renal collecting duct. In addition, PPARγ agonists decrease Na+ transport via the ENaC, leading to increases in systemic blood volume [29–31]. In fact, post marketing surveillance of pioglitazone showed that edema develops in 12.3% of all pioglitazone-treated diabetic patients [32]. Thus, pioglitazone may not always be appropriate for patients with NAFLD due to this adverse effect.

In our case, use of sitagliptin, a DPP-4 inhibitor, improved both the patient’s insulin resistance and her hepatic steatosis severity. Although the mechanisms for this were not clear, sitagliptin is known to improve glucose intolerance and hepatic steatosis in vivo [24, 33, 34]. GLP-1 agonists were reported to improve insulin resistance and hepatic steatosis in an animal model of NAFLD [24], and the use of a GLP-1 analog was also reported to improve hepatic steatosis in a patient with NAFLD [35]. Moreover, Gupta et al. [23] recently demonstrated that the the GLP-1 receptor is located in hepatocytes, and we also revealed that a GLP-1 analog directly increased glucose uptake in human hepatocytes through activation of the adenosine monophosphate kinase signaling pathways. Taken together, we hypothesized that sitagliptin improved insulin resistance and steatosis in this case.
In conclusion, we were the first to demonstrate that a DPP-4 inhibitor improved insulin resistance and steatosis in a patient with refractory NAFLD.

**Table 1. Characteristics of the patient**

|                        | Reference value | Patient’s value |
|------------------------|-----------------|-----------------|
| Age, years             | 64              | 64              |
| Gender                 | female          | female          |
| Height, cm             | 145.5           | 81.4            |
| Body mass index, kg/m² | 38.5            | 81.4            |
| Body fat mass, kg      | 43              | 43              |
| White blood cell count, /µl | 4,000–9,000 | 9,300           |
| Red blood cell count, /µl | 380–500 × 10⁴ | 506 × 10⁴       |
| Hemoglobin, g/dl       | 11.0–15.0       | 16.2            |
| Platelets, /µl         | 13.0–36.0 × 10⁴ | 24.8 × 10⁴     |
| Aspartate aminotransferase, U/l | 13–33     | 35              |
| Alanine aminotransferase, U/l | 6–30     | 47              |
| Lactate dehydrogenase, U/l | 119–229   | 203             |
| Alkaline phosphatase, U/l | 115–359   | 194             |
| γ-Glutamyltranspeptidase, U/l | 10–47    | 23              |
| Choline esterase, IU/l | 214–466        | 529             |
| Total protein, g/dl    | 6.70–8.30       | 8.35            |
| Albumin, g/dl          | 4.00–5.00       | 4.64            |
| Total bilirubin, mg/dl | 0.30–1.20       | 0.65            |
| Blood urea nitrogen, mg/dl | 8.0–22.0  | 14.9            |
| Creatinine, mg/dl      | 0.40–0.70       | 0.53            |
| Sodium ion, mEq/l      | 130–146         | 138             |
| Potassium ion, mEq/l   | 3.6–4.9         | 4.6             |
| Chloride ion, mEq/l    | 99–109          | 99              |
| Serum iron, µg/dl      | 80–170          | 104             |
| Ferritin, ng/ml        | 4.9–96.6        | 102.1           |
| Serum zinc, µg/dl      | 80–130          | 94              |
| Amylase, U/l           | 42–132          | 81              |
| Fasting glucose, mg/dl | 80–109          | 125             |
| Fasting insulin, µU/ml | 5.0–20.0        | 52.8            |
| HOMA-IR                | <2.5            | 16.3            |
| Hemoglobin A1c, %      | 4.3–5.8         | 7.8             |
| Total cholesterol, mg/dl | 128–219   | 223             |
| HDL cholesterol, mg/dl | 86.1–140        | 78.7            |
| LDL cholesterol, mg/dl | <139.0          | 130             |
| Triglyceride, mg/dl    | 40.0–96.0       | 118             |
| Free fatty acid, µmol/l | 100–540  | 1,400           |
| 3-Hydroxybutyric acid, µmol/l | <76     | 112             |
| Antimitochondrial antibody | negative | negative         |
| Antinuclear antibody   | negative        | negative        |
| α-Fetoprotein, ng/ml   | <8.7            | 3.9             |
| Hepatitis B surface antigen | negative | negative         |
| Hepatitis B core antigen | negative | negative        |
| Antibody to hepatitis C virus | negative | negative        |

HDL = High-density lipoprotein; LDL = low-density lipoprotein.
**Fig. 1.** Time course of body mass index and glucose metabolisms during the medical treatment.

**Fig. 2.** Changes in MRI imaging during the medical treatment. All images are T1 subtraction images.

**References**

1. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G: A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372–384.

2. Scaglioni F, Ciccio S, Marino M, Bedogni G, Bellentani S: ASH and NASH. Dig Dis 2011;29:202–210.

3. Regimbeau JM, Colombat M, Mognot P, Durand F, Abdulla E, Degott C, Degos F, Farges O, Belghiti J: Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004;10:569–573.

4. Starley BQ, Calcagno CJ, Harrison SA: Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010;51:1820–1832.
Lonardo A, Lombardini S, Ricchi M, Scaglioni F, Loria P: Review article: Hepatic steatosis and insulin resistance. Aliment Pharmacol Ther 2005;22:(suppl 2):64–70.

Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113–121.

Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, Charatcharoenwitthaya P, Topping JH, Bugianesi E, Day CP, George J: The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011;54:1208–1216.

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fiji, N, Musi N, Hirshman MF, Goodyear LJ, Möller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167–1174.

Kraßoff J, Clark JM, Crandall JP, Wilson C, Molitch ME, Brancati FL, Edelstein SL, Knowler WC: Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity (Silver Spring) 2010;18:1762–1767.

Greenhill C: Metformin, weight loss and NAFLD. Nat Rev Endocrinol 2010;6:296.

Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J: Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176–1184.

Bellort F, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297–2307.

Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KE, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Unalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR: Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659–1668.

Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675–1685.

Lovshin JA, Drucker DJ: Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262–269.

Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696–1705.

Burcelin R: The incretins: a link between nutrients and well-being. Br J Nutr 2005;93(suppl 1):S147–S156.

D’Alessio DA, Sandoval DA, Seeley RJ: New ways in which GLP-1 can regulate glucose homeostasis. J Clin Invest 2005;115:3406–3408.

Drucker DJ: Glucagon-like peptides. Diabetes 1998;47:159–169.

Knauf C, Cani PD, Ait-Belgnaoui A, Benani A, Dray C, Cabou C, Colom A, Uldry M, Rastrelli S, Sabatier E, Godet N, Waget A, Penicaud L, Valet P, Burcelin R: Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 2008;149:4768–4777.

Knauf C, Cani PD, Kim DH, Iglesias MA, Chabo C, Waget A, Colom A, Rastrelli S, Delzenne NM, Drucker DJ, Seeley RJ, Burcelin R: Role of central nervous system glucagon-like peptide-1 receptors in enteric glucose sensing. Diabetes 2008;57:2603–2612.

Saraceni C, Broderick TL: Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function. Drugs R D 2007;8:145–153.

Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA: Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010;51:1594–1592.

Ding X, Saxena NK, Lin S, Gupta NA, Anania FA: Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006;43:173–181.

Williams R: Global challenges in liver disease. Hepatology 2006;44:521–526.

Kawaguchi T, Shiba N, Maeda T, Matsugali T, Takano Y, Itou M, Sakata M, Taniguchi E, Nagata K, Sata M: Hybrid training of voluntary and electrical muscle contractions reduces steatosis, insulin resistance, and IL-6 levels in patients with NAFLD: a pilot study. J Gastroenterol 2011;46:746–757.
27 Kawaguchi T, Shiba N, Takano Y, Maeda T, Sata M: Hybrid training of voluntary and electrical muscle contractions decreased fasting blood glucose and serum interleukin-6 levels in elderly people: a pilot study. Appl Physiol Nutr Metab 2011;36:276–283.

28 Sood V, Colleran K, Burge MR: Thiazolidinediones: a comparative review of approved uses. Diabetes Technol Ther 2000;2:429–440.

29 Hummler E, Horisberger JD: Genetic disorders of membrane transport. V. The epithelial sodium channel and its implication in human diseases. Am J Physiol 1999;276:G567–G571.

30 Karpushev AV, Levchenko V, Pavlov TS, Lam VY, Vinnakota KC, Vandewalle A, Wakatsuki T, Staruschenko A: Regulation of ENaC expression at the cell surface by Rab11. Biochem Biophys Res Commun 2008;377:521–525.

31 Pavlov TS, Levchenko V, Karpushev AV, Vandewalle A, Staruschenko A: Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel. Mol Pharmacol 2009;76:1333–1340.

32 Kawamori R, Kadowaki T, Onji M, Seino Y, Akanuma Y: Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan. Diabetes Res Clin Pract 2007;76:229–235.

33 Maiztegui B, Borelli MI, Madrid VG, Del Zotto H, Raschia MA, Francini F, Massa ML, Flores LE, Rebolledo OR, Gagliardino JJ: Sitagliptin prevents the development of metabolic and hormonal disturbances, increased beta-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin Sci (Lond) 2011;120:73–80.

34 Souza-Mello V, Gregorio BM, Cardoso-de-Lemos FS, de Carvalho L, Aguila MB, Mandarim-de-Lacerda CA: Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin Sci (Lond) 2010;119:239–250.

35 Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ: Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006;26:1015–1017.